Literature DB >> 20879886

Healing the Syk through kinase inhibitors.

Juan Rivera, Robert A Colbert.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20879886     DOI: 10.1056/NEJMe1006527

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?

Authors:  José A Gómez-Puerta; Xavier Bosch
Journal:  Nat Rev Rheumatol       Date:  2011-02-08       Impact factor: 20.543

Review 2.  Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.

Authors:  David L Scott
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

3.  Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.

Authors:  Sumit Kunwar; Ashok Raj Devkota; Dipesh K C Ghimire
Journal:  Rheumatol Int       Date:  2016-04-25       Impact factor: 2.631

4.  Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells.

Authors:  Aurélien Naldi; Romain M Larive; Urszula Czerwinska; Serge Urbach; Philippe Montcourrier; Christian Roy; Jérôme Solassol; Gilles Freiss; Peter J Coopman; Ovidiu Radulescu
Journal:  PLoS Comput Biol       Date:  2017-03-17       Impact factor: 4.475

5.  Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.

Authors:  Marion Buffard; Aurélien Naldi; Gilles Freiss; Marcel Deckert; Ovidiu Radulescu; Peter J Coopman; Romain M Larive
Journal:  Biomolecules       Date:  2021-02-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.